Recap: Paratek Pharmaceuticals Q3 Earnings
Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM.
Here's what investors need to know about the announcement.
Paratek Pharmaceuticals’s Return On Capital Employed Insights
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also posted a total of $57.49 million in sales, a 249.98% increase since Q1.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value of their outstanding shares is at $47.1 million.
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Project BioShield contract. Related Link: Paratek’s…
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 27)
Paratek Pharma Reports $19M In Added Funding Under BARDA Contract To Advance Development Of NUZYRA For Post-Exposure Prophylaxis, Treatment Of Pulmonary Anthrax; BARD Contract Now Valued At $304M
-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program
-- BARDA Contract Now Valued at Up to ~$304M
-- Development Milestones Specified for Future Procurements
BOSTON, Sept. 27, 2021 (GLOBE
48 Biggest Movers From Friday
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.
